sunvozertinib (DZD9008)

Post-ASCO Lung Cancer: In this video, Drs. @JackWestMD, @christine_lovly, and @Alfdoc2 look at data on Sunvozertinib's use against EGFR Exon 20 NSCLC. https://t.co/xvqYxoFOok For more, please visit https://t.co/7Xpzj7KaFx. (@cancerGRACE)

Post-ASCO Lung Cancer: In this video, Drs. @JackWestMD, @christine_lovly, and Alfredo Addeo look at data on Sunvozertinib's use against EGFR Exon 20 NSCLC. https://t.co/xvqYxoFOok For more, please visit https://t.co/3VETMT8eM4. (@cancerGRACE)

Sunvozertinib EGFR exon20 ins inhibitor -ORR 60.8% across exon20ins subtypes -cORR 48.5% in pts with CNS mets -toxicity profile w/ high rates of diarrhea, rash, anemia #ASCO23 #LCSM @AnaVManana (@OncLive)

Amazing analysis by MD Riess at #ASCO23 about the first pivotal study that confirmed sunvozertinib is superior anti-tumor efficacy than the current available therapy for NSCLC with EGFR exon20ins 🙌 (@Dr_Ivanoncologo)

#ASCO23 @ASCO Abs#9002 Results of DZD9008 - sunvozertinib in pts w/ exon 20 #EGFR mutation @Exon20Group ➡️ Median 2L of prior tx ➡️ ORR ~ 61%, N=100 ➡️ ORR 48.5% in baseline brain mets ➡️ DoR 11 mo #LCSM https://t.co/ZfJY1gbtoS @OncoAlert @HemOncToday (@CharuAggarwalMD)

🔝 Sunvozertinib's superior anti-tumor efficacy outperforms current available therapy for NSCLC with EGFR exon20 insertion mutations. We're eagerly waiting for more data from this study and others around the world. 🌍 #ASCO23 #oncology #NSCLC" (@CAudigierValett)

📢 Breaking news from #ASCO23: The first pivotal study results are in for Sunvozertinib (DZD9008), a selectively designed EGFR exon20 insertion inhibitor, for the treatment of NSCLC. This is a major step in targeted cancer therapies. 🎯 #cancerresearch #NSCLC (@CAudigierValett)

New on @OncologyTube - Lung Cancer: My Top 5 Abstracts to See in Lung Cancer at #ASCO23 featuring Dr. @JackWestMD! 🎉🔬💪 🔗 Link: https://t.co/N8KSV7zwdb 📌 Abstracts: 1️⃣ ADAURA 2️⃣ KEYNOTE-671 3️⃣ KEYNOTE-789 4️⃣ Sunvozertinib 5️⃣ LUNAR @CityofHope #ASCOTop5 #LungCancer (@oncologytube)

Dr. @charocampelo gives an update on #EGFR exon 20 insertion NSCLC at #RomeLung23. Amivantamab and mobocertinib now approved but modest response rates. Newer agents coming like zipalertinib (CLN-081) and sunvozertinib (DZD9008). And despite data, IO is often used in real world. (@StephenVLiu)

Dr. @LudaBazhenovaMD presents data from sunvozertinib (DZD9008) in #EGFR exon 20 insertion NSCLC at #NACLC22. At 300mg, RR 52% (phase II WU-KONG 6 with RRR 60%). Activity across mutation position. Responses seen post amivantamab and CNS response noted. Important #EGFRex20 update. (@StephenVLiu)

#ASCO22 Overall, much progress in #EGFR exon 20 insertion NSCLC including data at this meeting on CLN-081, sunvozertinib, and osi/neci. Great discussion laced with optimism by Dr. @GRecondoMD (@StephenVLiu)

Preclinical and phase I experience with sunvozertinib (DZD9008), selective #EGFR TKI with FDA Breakthrough Designation in EGFR exon 20 insertion NSCLC. MTD 400mg daily. Diarrhea in 54% of pts (5% G3). Across dose levels, confirmed RR 38% in #EGFRex20. https://t.co/Bz60ogjUBS (@StephenVLiu)

#ELCC22 @Alfdoc2 provides a comprehensive overview of EGFR exon20ins beyond approved agents amivantamab & mobocertinib: - agents in developt: DZD9008, CLN081, incr dose osi - combinations - 1L trials: PAPILLON (ami + plt/pem); EXCLAIM-2 (mobo+ plt/pem) @oncoalert @myesmo #LCSM (@DrJNaidoo)

#WCLC21 Overall, DZD9008 shows encouraging activity in #EGFR exon 20 NSCLC across different types of mutations with some durability noted. Side note though, we had 5 great slides looking at efficacy from all angles but only 1 slide on safety with very few details... #LCSM (@StephenVLiu)

#WCLC21 Dr. Pasi Janne presents the phase I study of DZD9008 in #EGFR exon 20 insertion NSCLC. DZD9008 is an orally bioavailable irreversible EGFR inhibitor being developed for EGFR and #HER2 mutant NSCLC. This analysis is of the WU-KONG1 and WU-KONG2 trials. #LCSM @OncoAlert (@StephenVLiu)

Very strong activity of DZD9008 on #LCSM exon20ins EGFR+ patients, ORR 37%, DCR86%, mDOR NR, 53% diarrhea, 40% rash, 28% paronychia. Brain penetration unknown #ASCO21 (@jsoriamd)

DZD9008 results in exon 20 EGFR insertion: are 40%, good safety profile and oral admin. PFS results pending. Impressive early results! @ASCO #ASCO21 #LCSM @WinshipAtEmory (@RamalingamMD)

#ASCO21 DZD9008 is another irreversible EGFR TKI that has good preclinical activity. Included NSCLC with #EGFR and #HER2 exon 20 mutations with expansions at 200mg and 300mg once daily. #LCSM @OncoAlert @Exon20Group (@StephenVLiu)

#ASCO21 This was one an abstract that caught my attention: Dr. James Yang presenting the phase I data from DZD9008 (WU-KONG1/2). Note that this is also abstract #9008 (nice work @ASCO!) This is a novel TKI focused on EGFR exon 20 insertion mutations. #LCSM @OncoAlert (@StephenVLiu)

#ASCO21 Overall, this is one to watch. EGFR exon 20 insertion NSCLC has been a therapeutic challenge but now we have an approved agent (amivantamab), active TKIs (mobocertinib, poziotinib) and this new TKI with an impressive profile (DZD9008). What a difference a few years makes! (@StephenVLiu)

WU-KONG1&2 Ph1 trial of DZD9008, EGFR ex20ins TKI: typical EGFR TKI AEs observed; relative lower G3+ level; ORR=39.6% including those with CNS mets and prior ami; median DoR >3.5 months, currently limited f/up. Encouraging early data #ASCO21 #LCSM (@DrSanjayPopat)

James Yang: DZD9008 EGFR and Her2 irrevTKI. #ASCO21 #LCSM (@DrRiyazShah)